Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:58:56 EDT Sun 13 Jul 2025
Enter Symbol
or Name
USA
CA



Z:JNJ - JOHNSON & JOHNSON - https://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z0.1156.00·156.990.5156.90-0.78-0.57,872.11,224,22965,385157.085  157.18  155.18169.99  140.6819:38:49Jul 0815 min RT 2¢

Recent Trades - Last 10 of 65385
Time ETExPriceChangeVolume
19:38:49Z155.5012-2.18881
19:37:50Z156.90-0.791
19:36:41Z156.51-1.1825
19:36:31Z156.99-0.701
19:35:39Z156.99-0.701
19:33:15Z157.00-0.6910
19:16:19Z157.00-0.696
19:08:20Z156.80-0.899
18:52:25Z156.51-1.1810
18:50:03Z156.82-0.872

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-08 08:00U:JNJNews ReleaseSupplemental new drug application submitted to U.S. FDA for CAPLYTA(TM) (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
2025-06-23 07:32U:JNJNews ReleaseIMAAVY(TM) (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
2025-06-15 03:15U:JNJNews ReleaseInvestigational combination of first-in-class bispecifics TALVEY(TM) and TECVAYLI(TM) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
2025-06-13 11:00U:JNJNews ReleaseJohnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
2025-06-12 11:00U:JNJNews ReleaseNew results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
2025-06-11 08:05U:JNJNews ReleaseNew data show TREMFYA(TM) (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
2025-06-10 16:51U:JNJNews ReleaseJohnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
2025-06-03 10:45U:JNJNews ReleaseEarly results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
2025-06-03 10:45U:JNJNews ReleaseSingle infusion of CARVYKTI(TM) (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
2025-06-03 10:45U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
2025-06-03 08:00U:JNJNews ReleaseJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
2025-05-28 16:43U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2025-05-21 16:40U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
2025-05-20 18:21U:JNJNews ReleaseU.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
2025-05-14 16:40U:JNJNews ReleaseJohnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-09 08:05U:JNJNews ReleaseIcotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
2025-05-08 08:12U:JNJNews ReleaseJohnson & Johnson expands efforts to champion the nursing workforce globally
2025-05-05 08:05U:JNJNews ReleaseTREMFYA(TM) (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
2025-05-05 08:05U:JNJNews ReleaseTREMFYA(TM) (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
2025-04-30 08:29U:JNJNews ReleaseJohnson & Johnson receives FDA approval for IMAAVY(TM) (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)